Current Progress in Rheumatoid Arthritis

November 15-19, 2014; Boston, Massachusetts
Chad Deal, MD, explores the clinical significance of key studies in rheumatoid arthritis presented at the 2014 American College of Rheumatology Annual Meeting.
Chad Deal, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: March 5, 2015 Expiration: March 4, 2016

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the long-term impact of current treatment strategies in the management of patients with rheumatoid arthritis
  • Select initial therapy for a patient with active rheumatoid arthritis based on consideration of cost effectiveness in addition to efficacy and safety
  • Evaluate the safety of current treatments for rheumatoid arthritis based on currently available evidence

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Chad Deal, MD

Staff Physician
Orthopaedic & Rheumatologic Institute
Cleveland Clinic
Associate Professor of Medicine
Orthopaedic & Rheumatologic Institute
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University School of Medicine
Cleveland, Ohio

Chad Deal, MD, has disclosed that he has received consulting fees from Amgen and Lilly.

Staff

Andrew D. Bowser, ELS, CHCP

Director, Educational Strategy and Outcomes

Andrew D. Bowser, ELS, CCMEP, has no real or apparent conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for rheumatologists and other healthcare providers who manage patients with rheumatic diseases.

Goal

The goal of this program is to identify the most clinically significant data from the 2014 Boston meeting and translate those data to management strategies for patients with rheumatic diseases.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 05, 2015, through March 04, 2016:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

CCO faculty Dr. Jonathan Kay’s viewpoint on data from 2019 ACR/ARP on novel approaches for treatment of RA

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 9, 2020 Expiration: January 8, 2021

CCO faculty Dr. Stanley Cohen’s viewpoint on data from 2019 ACR/ARP on investigational and approved JAK inhibitors for RA

Stanley B. Cohen, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 5, 2019 Expiration: December 4, 2020

7-year baricitinib safety data in RA patients consistent with earlier reports and acceptable considering efficacy from 2019 ACR, as reported by CCO; safety evaluations ongoing

Released: November 25, 2019

Latest data on IRAK4 inhibitor PF-06650833 in moderately to severely active RA presented at ACR/ARHP 2019 as reported by Clinical Care Options (CCO)

Released: November 18, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?